Metoclopramide Accord

Metoclopramide, the active ingredient in Metoclopramide Accord, is a dopamine D2 receptor antagonist presented as an oral dosage form for systemic use. It is employed to relieve nausea and vomiting, improve gastric emptying in gastroparesis, and manage reflux‑related symptoms in adult patients.

GNH USA supplies Metoclopramide Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Customers benefit from consistent batch release and regulatory compliance across EU and other markets.

Metoclopramide is an antiemetic that acts on the chemoreceptor trigger zone and gastrointestinal motility.

- Nausea and vomiting: Reduces frequency and severity of symptoms in postoperative, chemotherapy‑induced, or other causes. - Gastroparesis: Enhances gastric emptying and alleviates associated discomfort. - Gastro‑oesophageal reflux disease: Improves lower oesophageal sphincter tone and reduces reflux episodes. - Migraine‑associated nausea: Controls nausea accompanying acute migraine attacks.

Metoclopramide may cause a range of adverse reactions.

Common Side Effects: - Drowsiness - Fatigue - Restlessness - Diarrhea

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia) - Tardive dyskinesia with prolonged use - Neuroleptic malignant syndrome

Use of Metoclopramide requires careful clinical assessment.

- Assess renal function: adjust use in severe renal impairment. - Monitor for extrapyramidal reactions: especially in elderly patients. - Avoid in patients with known hypersensitivity to metoclopramide. - Use caution in individuals with depression or suicidal ideation. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Metoclopramide can interact with several drug classes.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol): increased risk of extrapyramidal symptoms. - CYP2D6 inhibitors (e.g., fluoxetine): elevated metoclopramide plasma levels. - QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Opioids: may enhance anti‑nausea effect. - Anticholinergics: may diminish pro‑kinetic activity. - MAO inhibitors: possible additive central nervous system effects.